Phase 3 Trial Halted for Abecma in Newly Diagnosed Myeloma Patients
Key Developments in Myeloma Treatment
Bristol Myers Squibb (NYSE:BMY) and 2seventy Bio (NASDAQ:TSVT) have made a significant announcement regarding their phase 3 trial, KarMMa-9, involving the treatment Abecma. The trial has been halted for newly diagnosed myeloma patients.
Financial Implications
This decision is projected to save approximately $80 million. The companies are refocusing their strategy to ensure profitability by 2025, indicating a shift in their operational priorities.
Future Expectations
Despite the halt, both companies express confidence in strong growth, driven in part by the recent FDA approval secured in April.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.